Canine Atopic Dermatitis Market size to grow by USD 319.37 million from 2021 to 2026, Driven by the increase in pet humanization - Technavio

NEW YORK, April 12, 2023 /PRNewswire/ -- The canine atopic dermatitis market size is forecast to increase by USD 319.37 million from 2021 to 2026, at a CAGR of 7.75%, according to the recent market study by Technavio. The growth of the market will be driven by the increase in pet humanization, rising awareness about disease prevention and pet insurance, and the rising importance of the treatment of allergic conditions in animals. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View Sample Report. 

Technavio categorizes the global canine atopic dermatitis market Vendor Analysis:

Established vendors have strong financial abilities and technical expertise in offering high-quality products. Small-scale vendors compete with established vendors by using low pricing strategies and strengthening their customer base in local or regional markets. Technavio has extensively analyzed 15 major vendors, including Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc.

Vendor Offerings -

• Bioceltix Spolka Akcyjna - Under the brand name of Bioceltix, the company offers solutions for canine atopic dermatitis that are treated by removing allergens that cause sensitization.
• Dechra Pharmaceuticals Plc - Under the brand name of Dechra, the company offers solutions for canine atopic dermatitis that helps a dog who is constantly scratching or licking or may be suffering from atopic dermatitis.
• Elanco Animal Health Inc. - Under the brand name of Atopica, the company offers solutions for canine atopic dermatitis that effectively relieves itchiness and reduces skin lesions by providing proven long-term relief.

Charts & data tables about market and segment sizes for forecast period (2022-2026) have been covered in this report. Download The Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Get a holistic overview of the endoscopic closure devices market by industry experts to evaluate and develop growth strategies. Download the Sample

Market Segmentation:

This canine atopic dermatitis market research report extensively covers market segmentation by product (antihistamines, glucocorticoids, progestational compounds, and others) and geography (North America, Europe, Asia, and ROW).

• The market share growth by the antihistamines segment will be significant for the market growth during the forecast period. The term "antihistamines" refers to medications that are frequently used to treat allergies. Additionally, they aid in the management of dog skin allergies. As a result, the growth of this market segment will be fueled by antihistamine medications, which are the most commonly prescribed medication for the treatment of allergies and are highly cost-effective and readily available.

Market Dynamics:

Key DRIVERS:

• The increase in pet humanization is one of the major factors supporting the canine atopic dermatitis market growth. 
• To extend their pets' lives and improve their health, pet owners look for high-quality medical supplies and veterinary care. This is clear in both developing and developing markets.
• Pet owners all over the world are working to ensure that the ingredients and manufacturing standards of all pet care products are of the same high standard as those for humans.
• Younger pet owners are putting in extra effort to pamper their animals.
• During the forecast period, the demand for medications to treat canine atopic dermatitis will be driven by the ever-increasing expectations and demands for pet wellness products.

Major Trends:

• The increase in M&A is an emerging trend supporting the canine atopic dermatitis market growth. 
• Elanco Animal Health Inc.'s separation from Eli Lilly and Co. was completed in March 2019. In March 2021, Virbac acquired certain Elanco projects related to the creation of novel parasiticide products. Itrafungol and Clomicalm, two products for companion animals, were also granted worldwide rights by Virbac.
• The proposed acquisition of the Animal Health Division of Bayer AG by Elanco Animal Health Inc. was approved by the European Commission in 2020. The second-largest animal health company in the world was established as a result of this acquisition.
• During the forecast period, the market for drugs to treat canine atopic dermatitis will expand due to an increase in mergers and acquisitions.

Key Challenges:

• The stringent global regulatory requirements is a challenge hindering the canine atopic dermatitis market growth. 
• To avoid repercussions, manufacturers are required to adhere to the strict regulatory requirement that has been implemented.
• Before being imported from one nation to another, the brand-new medications for animals must first have an approved application.
• Approved new animal drug applications (NADA), abbreviated new animal drug applications (ANADA), investigational new animal drug applications (INAD), generic investigational new animal drug applications (JINDA), conditional approval (CNADA), and index listing are all examples of the drug applications.
• During the forecast period, the demand for medications to treat canine atopic dermatitis may be hampered by the existence of such stringent regulations.

To get detailed insights about inclusions and exclusions, buy the report 

Register for a free trial today and gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this canine atopic dermatitis Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the canine atopic dermatitis market between 2022 and 2026
• Precise estimation of the size of the canine atopic dermatitis market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the Canine Atopic Dermatitis Market across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Canine Atopic Dermatitis Market vendors

Related Reports:

The animal sedative market size is expected to increase by USD 190.96 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.85%. The report extensively covers animal sedative market segmentation by type (parenteral and oral) and geography (North America, Europe, Asia, and Rest of World (ROW)). The increasing prevalence of animal diseases is notably driving the animal sedative market growth.

The animal genetics market is estimated to grow at a CAGR of 5.48% between 2022 and 2027. The size of the market is forecast to increase by USD 1,534.79 million. This report extensively covers market segmentation by solution (live animal, genetic testing services, and genetic materials), end-user (research centers, hospitals and clinics, and diagnostic centers), and geography (North America, Europe, Asia, and Rest of World (ROW)). The growing demand for genetic testing services to reduce livestock diseases is notably driving the market growth.

Browse for Technavio's Health Care Market Reports

Table of contents

Executive Summary

Market Landscape

• Market ecosystem
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2021
• Market outlook: Forecast for 2021 - 2026

Five Forces Analysis

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Product

• Market segments
• Comparison by Product
• Antihistamines - Market size and forecast 2021-2026
• Glucocorticoids - Market size and forecast 2021-2026
• Progestational compounds - Market size and forecast 2021-2026
• Others - Market size and forecast 2021-2026
• Market opportunity by Product

Customer landscape

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2021-2026
• Europe - Market size and forecast 2021-2026
• Asia - Market size and forecast 2021-2026
• ROW - Market size and forecast 2021-2026
• Key leading countries
• Market opportunity by geography
• Market drivers
• Market challenges
• Market trends

Vendor Landscape

• Overview
• Landscape disruption

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• Bioceltix Spolka Akcyjna
• Ceva Sante Animale
• Dechra Pharmaceuticals Plc
• Elanco Animal Health Inc.
• Novartis AG
• Toray Industries Inc.
• Vetoquinol UK Ltd.
• Vimian Group AB
• Virbac
• Zoetis Inc.

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio